TNYA (Tenaya Therapeutics) Research & Development: $62.37 Mil (TTM As of Mar. 2026)


TNYA Tenaya Therapeutics Inc TNYA
32 GF Score
Price $0.73
! 4 Warning Signs
View Full Analysis

What is Tenaya Therapeutics Research & Development?

Tenaya Therapeutics TNYA +2.13% 32 Research & Development is $62.37 Mil as of Mar. 2026. GuruFocus rates TNYA with a GF Score™ of 32/100. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Tenaya Therapeutics's Research & Development for the three months ended in Mar. 2026 was $14.84 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $62.37 Mil.

Tenaya Therapeutics  (NAS:TNYA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Tenaya Therapeutics Research & Development Related Terms

Tenaya Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Tenaya Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tenaya Therapeutics Research & Development Chart

Tenaya Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 54.39 94.54 98.04 86.74 68.61

Tenaya Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.08 17.37 15.36 14.80 14.84
TNYA
32GF Score
Tenaya Therapeutics Inc TNYA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tenaya Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $62.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $62.37 Mil mean?
Tenaya Therapeutics (TNYA) has a Research & Development of $62.37 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Tenaya Therapeutics and its competitors.
Is Tenaya Therapeutics' Research & Development too high?
Tenaya Therapeutics' current Research & Development is $62.37 Mil. Overall, Tenaya Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Tenaya Therapeutics' Research & Development compare to MIST and NRXP?
Tenaya Therapeutics' Research & Development of $62.37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Tenaya Therapeutics and its competitors. Tenaya Therapeutics's current Research & Development is $62.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenaya Therapeutics stock overvalued right now?
Tenaya Therapeutics (TNYA) has a current Research & Development of $62.37 Mil. The current Research & Development is $62.37 Mil. Tenaya Therapeutics' overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Tenaya Therapeutics (TNYA), the current Research & Development is $62.37 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tenaya Therapeutics Business Description

Address 171 Oyster Point Boulevard, Suite 500, 5th Floor, South San Francisco, CA, USA, 94080
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
32GF Score

Get the complete analysis for TNYA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.73
Price